Perrigo (PRGO +0.5%) announces final FDA approval for its Ketoconazole Foam 2% treatment for dermatitis in younger patients. The company has commenced shipping of the product and has 180 days of marketing exclusivity.
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs